Answers are grounded in this paper and cite their sources.
Acid sphingomyelinase deficiency (ASMD) type B is a rare genetic disorder leading to enlargement of the spleen and liver, pulmonary dysfunction, and other symptoms. Cost-utility analyses are often conducted to quantify the value of new treatments, and these analyses require health state utilities. Therefore, the purpose of this study was to estimate utilities associated with varying levels of severity of adult and pediatric ASMD type B.
No takes yet. Share an insight, caveat, or question.
Matza et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: